AR110502A1 - Polinucleótidos y polipéptidos de adenovirus - Google Patents
Polinucleótidos y polipéptidos de adenovirusInfo
- Publication number
- AR110502A1 AR110502A1 ARP170103442A ARP170103442A AR110502A1 AR 110502 A1 AR110502 A1 AR 110502A1 AR P170103442 A ARP170103442 A AR P170103442A AR P170103442 A ARP170103442 A AR P170103442A AR 110502 A1 AR110502 A1 AR 110502A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- acid sequence
- seq
- polypeptide
- functional derivative
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 13
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 13
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 13
- 241000701161 unidentified adenovirus Species 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 19
- 102000040430 polynucleotide Human genes 0.000 abstract 7
- 108091033319 polynucleotide Proteins 0.000 abstract 7
- 239000002157 polynucleotide Substances 0.000 abstract 7
- 108700019146 Transgenes Proteins 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1620968.6A GB201620968D0 (en) | 2016-12-09 | 2016-12-09 | Adenovirus polynucleotides and polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110502A1 true AR110502A1 (es) | 2019-04-03 |
Family
ID=58222021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103442A AR110502A1 (es) | 2016-12-09 | 2017-12-07 | Polinucleótidos y polipéptidos de adenovirus |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11414679B2 (enExample) |
| EP (1) | EP3551224A1 (enExample) |
| JP (1) | JP2020511114A (enExample) |
| KR (1) | KR20190092471A (enExample) |
| CN (1) | CN110300597A (enExample) |
| AR (1) | AR110502A1 (enExample) |
| AU (1) | AU2017371944B2 (enExample) |
| BE (1) | BE1025029B1 (enExample) |
| BR (1) | BR112019010906A2 (enExample) |
| CA (1) | CA3045973A1 (enExample) |
| EA (1) | EA201991116A1 (enExample) |
| GB (1) | GB201620968D0 (enExample) |
| IL (1) | IL266942A (enExample) |
| MX (1) | MX2019006725A (enExample) |
| WO (1) | WO2018104911A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6576326B2 (ja) | 2013-03-14 | 2019-09-18 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍溶解性アデノウイルス組成物 |
| KR20220163505A (ko) | 2016-02-23 | 2022-12-09 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| GB201620968D0 (en) * | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
| JP2019536468A (ja) | 2016-12-12 | 2019-12-19 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍を標的にする合成アデノウイルスおよびその使用 |
| JP2020518648A (ja) | 2017-05-08 | 2020-06-25 | グリットストーン オンコロジー インコーポレイテッド | アルファウイルス新生抗原ベクター |
| EP3655536A1 (en) | 2017-07-17 | 2020-05-27 | GlaxoSmithKline Biologicals SA | Lyssavirus antigen constructs |
| WO2019076877A1 (en) * | 2017-10-16 | 2019-04-25 | Glaxosmithkline Biologicals Sa | ADENOVIRAL VECTORS FOR REPLICATION |
| AU2019251356B2 (en) | 2018-04-09 | 2025-06-12 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions with enhanced replication properties |
| EP3807298A1 (en) | 2018-06-12 | 2021-04-21 | GlaxoSmithKline Biologicals S.A. | Adenovirus polynucleotides and polypeptides |
| EP3833382A1 (en) | 2018-08-07 | 2021-06-16 | GlaxoSmithKline Biologicals S.A. | Processes and vaccines |
| WO2020128012A1 (en) | 2018-12-21 | 2020-06-25 | Glaxosmithkline Biologicals Sa | Methods of inducing an immune response |
| AU2020282369A1 (en) | 2019-05-30 | 2022-01-20 | Seattle Project Corp. | Modified adenoviruses |
| EP4133090A1 (en) * | 2020-04-07 | 2023-02-15 | Lung Biotechnology PBC | Adenoviral expression vector and methods and cell lines for production |
| WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
| JP2025523458A (ja) * | 2022-06-22 | 2025-07-23 | アスクバイオ インコーポレイテッド | アデノウイルスに基づく核酸およびその方法 |
| WO2025038011A1 (en) * | 2023-08-11 | 2025-02-20 | Joint Stock Company «Biocad» | Modified sequence of adenovirus e2a gene for producing vectors based on adeno-associated viruses (aav) (variants) |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| CA2085827C (en) | 1991-12-23 | 2003-10-14 | Lucas A. T. Hilgers | Adjuvant composition containing synthetic hydrophobic lipopolysaccharide |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| AU685443B2 (en) | 1993-03-23 | 1998-01-22 | Smithkline Beecham Biologicals (Sa) | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| ES2149340T3 (es) | 1993-11-17 | 2000-11-01 | Om Pharma | Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso. |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| DK0772619T4 (da) | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunmodulatoriske oligonukleotider |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
| JP2001500015A (ja) | 1996-09-06 | 2001-01-09 | トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法 |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| US6610661B1 (en) | 1996-10-11 | 2003-08-26 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| CA2654522C (en) | 1997-08-29 | 2014-01-28 | Antigenics Inc. | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| US6210663B1 (en) | 1998-08-20 | 2001-04-03 | The Wistar Institute Of Anatomy And Biology | Methods of augmenting mucosal immunity through systemic priming and mucosal boosting |
| CN101926993B (zh) | 1998-10-16 | 2013-12-04 | 史密丝克莱恩比彻姆生物有限公司 | 佐剂系统及疫苗 |
| US7291498B2 (en) | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| DE602005017743D1 (de) * | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| JP5475279B2 (ja) * | 2005-06-17 | 2014-04-16 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | Ｃ型肝炎ウイルス核酸ワクチン |
| CN105039372A (zh) | 2005-11-30 | 2015-11-11 | 哥本哈根大学 | 一种核苷酸疫苗 |
| JP2010522540A (ja) | 2007-03-21 | 2010-07-08 | アイディー バイオメディカル コーポレイション オブ ケベック | キメラ抗原 |
| KR101614369B1 (ko) * | 2007-11-28 | 2016-04-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 유인원 아과 ｃ 아데노바이러스 ｓａｄｖ-40, -31, 및 -34 및 그것의 사용 |
| EP2865387B1 (en) | 2008-11-21 | 2019-06-12 | Københavns Universitet (University Of Copenhagen) | Priming of an immune response |
| KR101763093B1 (ko) | 2009-02-02 | 2017-07-28 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도 |
| WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| CN103492574B (zh) | 2011-02-22 | 2015-12-09 | 加州理工学院 | 使用腺相关病毒（aav）载体递送蛋白 |
| WO2016198599A1 (en) * | 2015-06-12 | 2016-12-15 | Glaxosmithkline Biologicals S.A. | Adenovirus polynucleotides and polypeptides |
| GB201620968D0 (en) * | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
-
2016
- 2016-12-09 GB GBGB1620968.6A patent/GB201620968D0/en not_active Ceased
-
2017
- 2017-12-07 KR KR1020197018883A patent/KR20190092471A/ko not_active Ceased
- 2017-12-07 JP JP2019530815A patent/JP2020511114A/ja active Pending
- 2017-12-07 EA EA201991116A patent/EA201991116A1/ru unknown
- 2017-12-07 CA CA3045973A patent/CA3045973A1/en active Pending
- 2017-12-07 WO PCT/IB2017/057738 patent/WO2018104911A1/en not_active Ceased
- 2017-12-07 CN CN201780074539.3A patent/CN110300597A/zh active Pending
- 2017-12-07 MX MX2019006725A patent/MX2019006725A/es unknown
- 2017-12-07 US US16/466,683 patent/US11414679B2/en active Active
- 2017-12-07 BR BR112019010906A patent/BR112019010906A2/pt not_active IP Right Cessation
- 2017-12-07 AR ARP170103442A patent/AR110502A1/es unknown
- 2017-12-07 BE BE2017/5910A patent/BE1025029B1/fr not_active IP Right Cessation
- 2017-12-07 EP EP17838152.1A patent/EP3551224A1/en active Pending
- 2017-12-07 AU AU2017371944A patent/AU2017371944B2/en not_active Ceased
-
2019
- 2019-05-28 IL IL266942A patent/IL266942A/en unknown
-
2022
- 2022-05-11 US US17/742,221 patent/US11795478B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11414679B2 (en) | 2022-08-16 |
| JP2020511114A (ja) | 2020-04-16 |
| MX2019006725A (es) | 2019-08-22 |
| AU2017371944A1 (en) | 2019-06-20 |
| WO2018104911A1 (en) | 2018-06-14 |
| CN110300597A (zh) | 2019-10-01 |
| BR112019010906A2 (pt) | 2019-10-01 |
| US20190300905A1 (en) | 2019-10-03 |
| EA201991116A1 (ru) | 2019-12-30 |
| GB201620968D0 (en) | 2017-01-25 |
| BE1025029A1 (fr) | 2018-10-02 |
| AU2017371944B2 (en) | 2020-07-02 |
| IL266942A (en) | 2019-07-31 |
| BE1025029B1 (fr) | 2018-10-10 |
| US20220275397A1 (en) | 2022-09-01 |
| US11795478B2 (en) | 2023-10-24 |
| EP3551224A1 (en) | 2019-10-16 |
| KR20190092471A (ko) | 2019-08-07 |
| CA3045973A1 (en) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110502A1 (es) | Polinucleótidos y polipéptidos de adenovirus | |
| MX2024015050A (es) | L-asparaginasa modificada | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| ES2545895T3 (es) | Proteína de fusión anticancerígena | |
| CL2019002280A1 (es) | Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235) | |
| CO2019009525A2 (es) | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este | |
| ECSP15042898A (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
| AR114339A1 (es) | Plataforma de presentación, productos y métodos con endosporas basadas en paenibacillus | |
| BR112018000660A2 (pt) | peptídeos anti-inflamatórios e seu uso | |
| CL2019003410A1 (es) | Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407). | |
| AR065074A1 (es) | Peptidos de senalizacion | |
| CL2011000947A1 (es) | Polipeptido lectina; molecula de acido nucleico que la codifica; vector y celula hospedera; metodo para preparar el polipeptido; composicion farmaceutica que comprende el polipeptido; uso del polipeptido para preparar un medicamento para tratar transtorno autoinmune, inflamatorio o de piel dañada de un animal. | |
| ES2676542T3 (es) | Composiciones de CDV recombinante y usos de las mismas | |
| AR102324A1 (es) | Polipéptidos fhbp (proteína de unión al factor h) meningocócicos modificados | |
| CR20220501A (es) | Composiciones y métodos para la inducción de una respuesta inmune | |
| PE20230486A1 (es) | Polipeptidos y sus usos | |
| CL2017003097A1 (es) | Composiciones y métodos para el tratamiento de la enfermedad celiaca | |
| PE20220429A1 (es) | Vectores viricos que codifican variantes del fviii recombinantes con mayor expresion para la genoterapia de la hemofilia a | |
| AR074055A1 (es) | Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodo | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| CO2018001339A2 (es) | Sistema vector de adenovirus aviar 9 (fadv-9) y métodos asociados | |
| AR103586A1 (es) | Proteínas quiméricas que mejoran la actividad de los dominios de unión a adn y factores de transcripción en plantas | |
| AR123189A1 (es) | VACUNA DE SINUCLEÍNA a PARA EL TRATAMIENTO DE SINUCLEINOPATÍAS | |
| CL2020002246A1 (es) | Expresión de proteína de superficie a neumocócica (pspa) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |